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Abstract
Use of antiretrovirals is widespread in Brazil, where more than 200,000 individuals are under
treatment. Although general prevalence of primary antiretroviral resistance in Brazil is low,
systematic sampling in large metropolitan areas has not being performed.
The HIV Threshold Survey methodology (HIV-THS, WHO) was utilized, targeting Brazil's four
major regions and selecting the six most populated state capitals: Sao Paulo, Rio de Janeiro,
Salvador, Porto Alegre, Brasilia and Belem. We were able to sequence samples from 210 individuals
with recent HIV diagnosis, 17 of them (8.1%) carrying HIV isolates with primary antiretroviral
resistance mutations. Five, nine and four isolates showed mutations related to resistance to
nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase
inhibitors (NNRTIs) and protease inhibitors (PIs), respectively. Using HIV-THS, we could find an
intermediate level of transmitted resistance (5% to 15%) in Belem/Brasilia, Sao Paulo and Rio de
Janeiro. Lower level of transmitted resistance (<5%) were observed in the other areas. Despite the
extensive antiretroviral exposure and high rates of virologic antiretroviral failure in Brazil, the
general prevalence of primary resistance is still low. However, an intermediate level of primary
resistance was found in the four major Brazilian cities, confirming the critical need to start larger
sampling surveys to better define the risk factors associated with transmission of resistant HIV.
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Findings
In the mid '90s, the Brazilian government took a major
step in the fight against HIV/AIDS, making antiretrovirals
available free to all infected individuals. In addition, a
strong prevention programme was established to curb
new infections. As a result of these strategies, AIDS-related
mortality rates, which peaked in 1995/6, have declined
continually, and the number of infected individuals stabi-
lized at lower figures, which contradicts earlier worst-case
predicted scenarios [1].
However, given the sequential use of antiretroviral drugs
in many patients at the beginning of this programme, the
proportion of patients experiencing virologic failure is
assumed to be high. In fact, one study, done in 2002 with
patients on treatment in 1999/2000, showed that the
median time for benefit of initial treatment was approxi-
mately 14 months among treatment-naïve patients [2].
Another study revealed that only 27.5% of patients main-
tained undetectable viral loads after one year of follow up.
With the introduction of new drugs and more potent reg-
imens, the level of efficacy of initial treatment increased
substantially in Brazil.
HIV primary and secondary antiretroviral resistance is of
major concern in a country such as Brazil, where there is
widespread access to antiretroviral therapy. A study con-
ducted in Brazil, which analyzed 2474 samples from
patients on highly active antiretroviral treatment and who
had virologic failure, showed that 95% presented with
mutations related to antiretroviral resistance and of them,
21%, 45% and 34% presented resistance to one, two or
three classes of antiretroviral drugs, respectively [3].
In contrast, the frequency of primary resistance is much
lower. Several independent surveys carried out in Brazil-
ian cities, which analyzed drug-naïve populations selected
from recently and chronically infected individuals,
showed resistance rates varying from 1.4% to 8.3% [4,5].
These numbers are not different from that observed in
developed countries, where transmission of resistant
viruses to one or more antiretroviral agent has been
reported since 1993.
For instance, surveys conducted in developed countries
during the past decade and targeting recent seroconverters
have shown prevalence rates of 10% to 17% in France,
13% in German, 14% in the United Kingdom, 15% to
26% in North America, and 23% to 26% in Spain [6-17].
Recent surveys performed in the USA and Europe in com-
parable populations pointed out a slight increase in pri-
mary resistance prevalence, especially to non-nucleoside
reverse transcriptase inhibitors (NNRTIs) [10]. A contrast
to this picture is the low prevalence of primary drug-resist-
ance mutation in South America and the Caribbean
(<4%) [18-20].
In order to monitor the transmission of drug-resistant
strains and the subtype profile in Brazil, a National Net-
work for Drug Resistance Surveillance (HIV-BResNet) in
the chronically infected drug-naïve population was estab-
lished in 2000. The first survey, done in 2001, showed an
overall primary resistance rate of 6.6% with even distribu-
tion of NRTI, NNRTI and protease inhibitor (PI) resist-
ance-related mutations [21]. Here, we describe the results
of a new HIV-BResNet survey, conducted in 2007/8 on
recently diagnosed HIV patients seeking treatment in
AIDS clinics located in six major cities.
Threshold Survey developed by the World Health Organ-
ization (WHO), was utilized to compare primary resist-
ance levels in patients in these cities. In this study, we
targeted the four major country regions by selecting the six
most populated state capitals (Sao Paulo, Rio de Janeiro,
Salvador, Porto Alegre, Brasilia and Belem), accounting
for more than 70% of the Brazilian HIV/AIDS epidemic
and the majority of patients under antiretroviral treat-
ment. The major clinical labs, where most recent diag-
nosed individuals have their first CD4+ T cell counts and
viral loads determinations, were selected to conduct the
patient selection, as well as genotypic analysis.
The inclusion criteria was homogeneous across the sites:
participating individuals had to have received their HIV
diagnosis in the past six months, not have been exposed
to antiretroviral drugs for any reason, and had to be more
than 18 years old. Individuals were selected to the study
and were invited to read and sign informed consents.
Samples were collected sequentially until 47 samples were
reached and the questionnaire was completed. Samples
were analyzed in the same order of inclusion in each site
and were amplified and sequenced. This study received an
institutional review board (IRB) approval (CONEP,
IRB#9772), and informed consents were obtained from
all participating individuals.
For genotypic analysis ViroSeq™ v2.0 (Celera Diagnostics,
Alameda, California, USA) or TrueGene™ (Siemens Diag-
nostics, USA) were used. Mutation lists, as well as FASTA
files generated by commercial software, were further eval-
uated according to published guidelines, which exclude
common polymorphisms [22]. For subtype assignment,
we first separated protease and reverse transcriptase cod-
ing regions and submitted the data to the Stanford HIVDR
website. For quality assurance purposes, we re-sequenced
10% of samples in target sites..
The sample size and statistical approach from this survey
was adapted from WHO's HIV drug resistance ThresholdJournal of the International AIDS Society 2009, 12:20 http://www.jiasociety.org/content/12/1/20
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Survey (HIV DR THS) protocol [23]. Each city or region
was treated as an independent sampling event, and a
binomial sequential strategy was utilized: 47 consecutive
HIV-positive specimens were collected and genotyped.
The HIV drug resistance prevalence can be categorized
into three different levels: low (<5%), moderate (5% to
10%), and high (>15%). The analysis can be stopped at
the 34 initial specimens if the prevalence can be catego-
rized as low (<5%, if n ≤ 1) or high (>15%, if n ≥ 6). If it
is not met, an additional 13 specimens need to be geno-
typed to precisely calculate the prevalence categories.
We were able to study 223 individuals in six sites. Their
clinical and demographic characteristics are depicted in
Table 1. The male:female ratio of our selected individuals
was 0.95:1.05, and the average age was 36 years old. The
average CD4+ T cell count was 577 cells/mm3, which sug-
gests that the selected individuals were in the initial,
asymptomatic stage of HIV infection.
We could successfully amplify and sequence 210 speci-
mens, and found 17 (8.1%) isolates carrying primary
drug-resistance mutations. Five, nine and four isolates
showed mutations related to resistance to NRTIs, NNRTIs
and PIs, respectively. The more prevalent were mutations
related to NNRTI (K103N and Y188L/I), followed by
NRTI and PI (Table 2). The main PI mutation found was
M46I (three individuals), followed by L90M (one individ-
ual). Interestingly, most PI mutations were found in Rio
de Janeiro. There was a clear geographic trend in primary
resistance. We found an intermediate level of transmitted
resistance (5% to 15%) in Belem/Brasilia, Sao Paulo and
Rio de Janeiro, contrasting with the other sites, where a
lower level of transmitted resistance (<5%) was observed.
Comparing this prevalence with the data obtained in the
BResNet survey performed in 2002, it can be observed
that the primary resistance in Brazil remains at a stable
level, 6.6% in 2002 versus 8.1 in this latest BResNet sur-
vey. In support of this fact, lower levels of transmitted
resistance have been detected in other surveys done in
major cities, such as Sao Paulo, Rio de Janeiro and Porto
Alegre [24-26]. On the other hand, other studies have
demonstrated distinct levels of transmitted resistance in
other geographic areas; for example, higher levels of pri-
mary resistance have been detected in Santos and Salva-
dor [27,28].
Table 1: Epidemiological and subtype distribution of individuals included in this survey
Epidemiological data  Subtype distribution (%)
Characteristics Number B C F URF Others
Gender (male) 45% Sao Paulo (n = 47) 82 6 6 6 0
Age (years) 36 ± 8 Rio de Janeiro (n = 47) 87 2 2 9 0
Risk factor for HIV (%) Salvador (n = 34) 70 3 21 3 3
Homosexual 23.6 Porto Alegre (n = 34) 28 69 0 3 0
Bisexual 11 Belem/Brasilia (n = 48) 84 6 6 4 0
Heterosexual 56.1
Intravenous drug user 0
Blood transfusion 1.6
Other/multiple 8.7
Biological parameters
CD4 (cells/mm3)a 575 ± 221
Viral load (log of copies/ml)b 4.58 ± 4.75
a, and b Calculation based on 187 and 156 individuals who responded to this item on the questionnaire, respectively.Journal of the International AIDS Society 2009, 12:20 http://www.jiasociety.org/content/12/1/20
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This study was not designed to evaluate the subtype distri-
bution and the sample size was very limited in each of the
sites sampled. However, we were able to observe that the
subtype distribution found closely reflects previous data
generated in Brazil. Subtype B was the more prevalent
subtype found in all cities sampled (72%), except for
Porto Alegre, where a large proportion of HIV-1 subtype C
was observed (69%). This rate seems higher than the rate
described in this city in HIV ResNet in 2002 (45%), sug-
gesting an increase of this non-B subtype in this country
region [21].
Subtype F and several BF mosaics as well Unique Recom-
binant Forms (URFs) are the other major non-B strain
spread throughout the country and corresponds to
approximately 13% of the samples analyzed in our study.
Interestingly, a CRF2 (A/G) isolate was found in Salvador
Bahia, corroborating previous reports regarding the intro-
duction of this west African strain in Brazil [29].
Some studies have demonstrated that the time to obtain a
viral load below the detection limit may be increased
among individuals with primary resistance [30]. Regard-
less of high antiretroviral exposure levels and high rates of
virologic antiretroviral failure found in Brazil, the general
prevalence of primary antiretroviral resistance is still low.
However, intermediate level of primary resistance was
found in our four major cities, suggesting that more
noticeable resistance is transmitted in these areas.
Of note, mutation K103N had a significant increase when
the rate observed in 2002 (0.24%) is compared to the one
found this study (3.3%; P < 0.001 chi-square). This fact
probably reflects the widespread use of efavirenz in the
first drug regimen in Brazil. Therefore, it is critical to start
larger sampling surveys to better define the risk factors
associated with transmission of primary resistance, as well
as strengthen the prevention programmes targeting HIV-
positive individuals in antiretroviral therapy. An increased
prevalence of K103N can be a risk in the long run for the
usage of NNRTI-based first-line antiretroviral regimens in
Brazil.
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